Article
A Plasmodium falciparum genetic cross reveals the contributions of pfcrt and plasmepsin II/III to piperaquine drug resistance.
mBio - 17 Jul 2024
Kane John, Li Xue, Kumar Sudhir, Button-Simons Katrina A, Vendrely Brenneman Katelyn M, Dahlhoff Haley, Sievert Mackenzie A C, Checkley Lisa A, Shoue Douglas A, Singh Puspendra P, Abatiyow Biley A, Haile Meseret T, Nair Shalini, Reyes Ann, Tripura Rupam, Peto Thomas J, Lek Dysoley, Mukherjee Angana, Kappe Stefan H I, Dhorda Mehul, Nkhoma Standwell C, Cheeseman Ian H, Vaughan Ashley M, Anderson Timothy J C, Ferdig Michael T
Abstract excerpt
Piperaquine (PPQ) is widely used in combination with dihydroartemisinin as a first-line treatment against malaria. Multiple genetic drivers of PPQ resistance have been reported, including mutations in the Plasmodium falciparum chloroquine resistance transporter (pfcrt) and increased copies of plasmepsin II/III (pm2/3). We generated a cross between a Cambodia-derived multidrug-resistant KEL1/PLA1 lineage isolate...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
